Staphylococcus aureus

Latest Headlines

Latest Headlines

Pfizer brings S. aureus jab to PhIIb as it keeps the gas on vaccines expansion

Pfizer CEO Ian Read has long maintained that the company's vaccines unit should expand beyond the superstar pneumococcal disease blocker Prevenar. In addition to several moves last year and into this year, the company continued that work this week with the announcement of a "pivotal" trial for a surgical site infection candidate.

Pfizer, GSK and NovaDigm race to develop MRSA vaccine

Pfizer ($PFE), GlaxoSmithKline ($GSK) and NovaDigm Therapeutics are each in search of a vaccine to put a stop to methicillin-resistant Staphylococcus aureus, known as MRSA, a staph infection that kills more people in the United States than skin cancer, Bloomberg reports.

First 'cross-kingdom' vax effective in PhI

NovaDigm Therapeutics is developing a vaccine that could work against both bacteria and fungi, and could even combat resistant bacteria such as MRSA. The company presented Phase I results at the 15th Annual Conference on Vaccine Research.